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Abstract: Premature ejaculation (PE) is the most common sexual problem affecting men. 
It can affect men at all ages and has a serious impact on the quality of life for men and their 
partners. Currently there are no pharmaceutical agents approved for use in the UK, and so all 
drugs used for this condition are off label. Behavioral therapy has been used to treat PE, but the 
results are not durable once therapy has been concluded. Several topical therapies have been 
used including severance-secret (SS) cream, lignocaine spray, lidocaine-prilocaine cream and 
lidocaine-prilocaine spray (TEMPE). There has been recent interest in the selective serotonin 
reuptake inhibitors (SSRIs) for the treatment of PE, due to the fact that one of their common side 
effects is delayed ejaculation. Currently used SSRIs have several non-sexual side effects and 
long half lives, therefore there has been interest in developing a short acting, efficacious SSRI 
that can be used on-demand for PE. Dapoxetine has been recently evaluated for the treatment 
of PE by several groups, and results so far appear promising.
Keywords: premature ejaculation, topical therapies, selective serotonin re-uptake inhibitor, 
dapoxetine
Introduction
Premature ejaculation (PE), early or rapid ejaculation is the most common sexual 
disorder affecting men. A national study of sexual attitudes and lifestyles found PE 
lasting 1 month in the previous year to have a prevalence of 11.7% and 6 months in 
the previous year had a prevalence of 2.9%.1 Unlike erectile dysfunction (ED), PE 
affects men of all ages equally but like ED can have a serious impact on quality of 
life for both the patient and his partner. It may be lifelong, present since the onset of 
sexual maturity, or can be acquired after previously normal ejaculation, for example 
after a urological or psychological event. It has been suggested that there may be 
other forms of PE, including premature-like ejaculatory dysfunction where men 
with normal ejaculatory latency times perceive their ejaculation to be premature, and 
natural variable PE which might occur in a specific situation.2 The diagnosis of PE 
is evolving, however, one recommended definition of PE is persistent or recurrent 
ejaculation that occurs with minimal sexual stimulation before, on or shortly after 
penetration and before the person wishes it to; and over which the sufferer has no 
voluntary control, which causes marked distress or interpersonal difficulties. It can-
not be due to the direct effects of a substance (Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition, text revision, [DSM-IV-TR]). The International 
Society for Sexual Medicine (ISSM) definition states that PE is “A male sexual dys-
function characterized by ejaculation which is always or nearly always occurs prior Drug Design, Development and Therapy 2010:4 
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to or within 1 minute of vaginal penetration; and an inability 
to delay ejaculation on all or nearly all vaginal penetrations, 
and negative personal consequences, such as distress, bother, 
frustration, and/or the avoidance of sexual intimacy.”3 In 
practice the intra-vaginal ejaculatory latency time (IELT) is 
often used as a method of quantifying the response to treat-
ment and as a standardized method of comparing treatments 
within clinical trials. The IELT is defined as the time from 
vaginal intromission to intravaginal ejaculation.4
Until relatively recently PE was treated mainly by 
behavioral techniques, eg, the “squeeze technique” which 
was first described by Masters and Johnson in 1970,5 and 
the “stop–start method” described by Semans in 1956.6 
Despite the high prevalence of this condition, there is little 
research regarding its causation. It is likely that both bio-
logical and psychological factors have a role to play. Penile 
hypersensitivity, hyperexcitable ejaculatory reflex, increased 
sexual arousability, possible endocrinopathy; genetic pre-
disposition and 5-hydroxy-tryptamine (5-HT) receptor 
dysfunction have all been implicated as being biological 
causative factors.7 Several psychological risk factors have 
been implicated including anxiety, social phobia, relation-
ship problems, infrequent sexual intercourse and lack of 
sexual experience.8
At the present time there are no pharmacological agents 
approved in the UK for use in PE and all drugs are therefore 
used “off-label”. There are several treatment options avail-
able to men with PE. These include behavioral therapy, topi-
cal therapies, and systemic pharmacological agents.
Behavioral therapies
Behavioral therapies include the ‘stop-start’ and ‘squeeze 
technique’; these require commitment from the man and his 
partner, as well as the availability and instruction from well 
trained sex therapists. The stop–start technique involves the 
man stimulating himself to the point just before ejaculation, 
and then stopping. Once the sensations have subsided, he starts 
again. This should be repeated three times. The length of time 
before each stop gets gradually longer. The squeeze technique 
involves the partner (or man) using their fingers to squeeze the 
head (glans) of the penis to cause the erection (and ejaculation) 
to subside. Unfortunately most men do not show any lasting 
improvement using either of these techniques.9
Pharmacological treatment
Topical agents
The theory that men with PE may have penile hypersensitivity 
provides a rationale for using topical agents for example 
topical desensitizing agents. The use of local anesthetic 
treatment to delay ejaculation was first described by Schapiro 
in 1943.10 Topical agents are very attractive as they can be used 
on an as needed basis and systemic side effects are likely to 
be minimal. They are reported to be very efficacious, however 
studies are often small and there are often local side effects.
Severance-secret (SS) cream
SS cream (Cheil Jedan Corporation, Seoul, Korea) is a mix-
ture of nine traditional medicines, including Korean ginseng, 
bufonoid venom and cinnamon. Some of these have local anes-
thetic as well as vasoactive properties. In a randomized, double-
blind, placebo-controlled trial of SS-cream versus placebo, 
there was an increase in mean IELT from 1.37 minutes before 
treatment to 10.92 minutes in the SS-cream group.11 SS cream is 
available for use only in Korea and all of the studies evaluating 
its efficacy have been performed there and by the same research 
group. It has to be used an hour before intercourse and washed 
off immediately before intercourse, and some patients com-
plain that it has an unpleasant smell and color. Subsequently 
a renewed SS cream has been formulated that has the two main 
components of the SS cream, namely Korean ginseng and 
bufonoid venom in a hydrobase with an enhancer, yet without 
the smell and color of the original SS cream.12 SS cream is not 
approved for use in Europe or the USA.
Lignocaine spray
Marketed as Stud 100 or Premjact, this spray has been avail-
able for many years, and can be bought over the counter 
without a prescription. The active ingredient within the spray 
is the local anesthetic lignocaine (9.6%). Theoretically this 
spray would work in the same way as other topical anesthetic 
agents, however there is a paucity of data from clinical trials 
to support its use.
Lidocaine–prilocaine cream
The eutectic mixture of local anesthetic (EMLA™; AstraZeneca, 
London, UK) is a local anesthetic cream that contains 2.5% 
of both lidocaine and prilocaine for topical application. Trials 
using this topically in men with PE are small. In a trial of 42 men 
of whom only 29 completed the study, the IELT increased from 
1.49 minutes to 8.45 minutes following 2 months use of this 
local anesthetic cream. However genital hypoesthesia has been 
reported in both sexes in this study.13
Lidocaine–prilocaine spray
Topical eutectic mixture for premature ejaculation (TEMPE 
Plethora Solutions PLC, London, UK) is a formulation of Drug Design, Development and Therapy 2010:4 
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lignocaine and prilocaine in a metered dose aerosol-delivery 
system. Each spray delivers 7.5 mg of lidocaine and 2.5 mg 
of prilocaine. It is fast acting and appears to be efficacious 
in small studies. It does not penetrate keratinized epithe-
lium, and so only anesthetizes the glans; however there 
still appears to be some hypoesthesia associated with its 
use.14 In a phase II trial of 56 patients, TEMPE increased 
the IELT 2.4 × higher than placebo.14 In a larger multicenter 
phase III trial of 300 patients, TEMPE increased the IELT 
from 0.6 minutes to 3.8 minutes and was well tolerated 
by patients and partners as well as being rated good 
or excellent by 66% of patients using the treatment.15 
Although hypoesthesia has not been a reported problem 
in the female partners, there has been a small number of 
women who have reported a burning sensation during 
intercourse.14,15
Dyclonine/alprostadil
Dyclonine is a local anesthetic usually used in the field of 
dentistry. It has been combined with the vasodilator alprosta-
dil, and used to treat PE. The product is applied to the tip of 
the penis in the region of the meatus. One pilot study claims 
positive results with it, however the data is limited and fur-
ther studies are warranted before conclusions regarding this 
combination can be drawn.16
Systemic therapies
Tramadol
The oral opioid analgesic tramadol (Ultram®; Johnson & 
Johnson, NJ, USA) has been used as a treatment for PE. 
It is a centrally acting analgesic with two mechanisms of 
action. It exerts an effect on the µ-opioid receptor, but also 
inhibits noradrenaline and serotonin reuptake. Its mechanism 
of action in PE is poorly understood, however it is thought 
to be related to its action on the µ-opioid receptor, which 
may reduce sensitivity, as well as the inhibition of serotonin 
reuptake, which may delay ejaculation. There have been two 
small clinical trials and both showed a significant increase 
in the IELT compared with placebo.17,18 A study of 60 men 
comparing 25 mg of tramadol to placebo in a single blind 
cross-over study showed that tramadol increased the IELT 
from 1.17 minutes to 7.37 minutes. Tramadol increased 
patients’ control of ejaculation as well their sexual satis-
faction.17 A further study of 64 men comparing 50 mg of 
tramadol with placebo showed an increase in IELT from 
19 seconds to over 4 minutes in the tramadol arm.18 Although 
results from these studies are encouraging, further studies 
are warranted.
Clomipramine
Clomipramine (Anafranil™; Mallinckrodt pharmaceutical 
Products, MS, USA) is a tricyclic antidepressant that inhibits 
the reuptake of noradrenaline and serotonin. It is commonly 
used in the treatment of obsessive-compulsive disorders. 
Studies have used continuous dosing as well as on-demand 
dosing and shown significant increases in the IELT.19,20 
A meta-analysis evaluating the systemic treatments for PE, 
found clomipramine to be efficacious, particularly continuous 
dosing, results also showed it to be comparable to the selec-
tive serotonin re-uptake inhibitors (SSRIs) in its effects.19 
On demand clomipramine has been shown to increase the 
IELT 4-fold, however patients did have a high incidence of 
side effects.20
Serotonergic antidepressants
Psychotropic medications, for example SSRIs, have been 
used to delay ejaculation, and in fact can prolong intra-vaginal 
ejaculatory latency time for several minutes. They are usually 
used for the treatment of depression, and it was noted that 
delayed ejaculation was one of their common side-effects. 
They are often used at lower doses than when used to treat 
depression. Side effects include dry mouth, drowsiness, 
nausea and reduced libido as well as erectile dysfunction21. 
Currently four SSRIs are commonly used in the treatment 
of PE, Fluoxetine (Prozac®; Eli Lilly, IN, USA), parox-
etine (Paxil®; GlaxoSmithKline PLC, PA, USA), sertraline 
(Zoloft®; Pfizer, NY, USA) and citalopram (Celexa®; Forest 
Laboratories, NY, USA).
At least three serotonin receptor subtypes have been iden-
tified as having a role in ejaculation, these include 5-HT1a, 
5-HT1b and 5-HT2c. Activation of 5-HT1a receptor has a 
pro-ejaculatory effect, however activation of the 5-HT1b and 
5-HT2c delays ejaculation.21 To prevent overstimulation of 
post-synaptic 5-HT receptors, 5-HT transporters immediately 
remove the 5-HT from the synapse back into the pre-synaptic 
neurone.22
Serotonin is released from the pre-synaptic neurons into 
the synapse and it activates the 5-HT1B receptors. This results 
in reduced release of serotonin in the synapse. The SSRI’s 
block 5-HT transporter mechanisms and so increase 5-HT 
within the synapses. This in turn activates 5-HT1A and 5-HT1B 
receptors resulting in inhibition of serotonin release into the 
synaptic cleft. The result is sustained mild stimulation of all 
post-synaptic 5-HT receptors. After several days to weeks 
of SSRI treatment, the receptors become desensitized and 
so there is a reduction of that inhibitory action they have 
on serotonin release. The overall effect is more serotonin Drug Design, Development and Therapy 2010:4 
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released into the synapse.8 Activation of 5-HT2C receptors 
adjusts the ejaculatory set point and delays ejaculation, 
however the extent of this delay depends on several factors 
including the type, dose and frequency of the SSRI admin-
istration as well as the genetically determined ejaculatory 
threshold set point.23
Paroxetine, sertraline, and fluoxetine have all been evalu-
ated in patients with PE, paroxetine however has been found 
to have substantially greater efficacy, followed by sertraline 
and fluoxetine.19 Unfortunately these drugs have other sexual 
side effects, reduced libido, anorgasmia and erectile dysfunc-
tion have been observed with all of those drugs.21 The other 
nonsexual side effects of SSRIs include insomnia, fatigue, 
nausea, constipation and loss of appetite. Abrupt cessation or 
reduction of SSRI therapy can be associated with a discon-
tinuation syndrome. Symptoms include dizziness, nausea or 
vomiting, fatigue, headaches, ataxia, lethargy, anxiety, agita-
tion and insomnia. Symptoms begin from 24 to 72 hours after 
discontinuance and may last more than a week. It is generally 
recommended that SSRIs should not be stopped suddenly 
but reduced over several weeks.23 This is thought to be more 
common with the SSRIs that have shorter half lives.21
The side effect profile of the SSRIss taken on a chronic 
basis has led to the suggestion that an “on-demand” SSRI 
may be useful for PE. Waldinger and colleagues have evalu-
ated this using 25 mg clomipramine and 20 mg paroxetine. 
Although there was a clear benefit with clomipramine, par-
oxetine on the other hand did not show a significant increase 
in IELT when used in this manner.20 Abdel-Hamid and col-
leagues evaluated the effects of SSRIs on an as needed basis 
and found that paroxetine was superior to the pause-squeeze 
method, however only by a modest increase in the median 
IELT, 3 minutes for the squeeze technique and 4 minutes for 
paroxetine from a baseline of 1 minute.24
It has been postulated that on-demand treatment for PE 
with the conventional SSRIs would only be successful when 
combined with a 5-HT1A receptor antagonist or some other 
treatment that would acutely stimulate serotonin release.4 
5-HT1A receptor antagonists in the pre-clinical setting have 
been shown to delay ejaculation when used concomitantly 
and acutely with an SSRI, but were not effective on delay-
ing ejaculation when used alone.16 This is very promising, 
however further studies are required before conclusions can 
be drawn regarding this combination.
Although SSRIs do have a role in the treatment of PE, 
they must be used with caution and patients must be warned 
that there is a risk of suicidal ideation associated with the 
use of this class of drugs. Patients must be followed up and 
documentation that they are aware that their use is “off-label” 
and of the small but relevant suicide risk.
The need for an on-demand efficacious medication for 
the treatment of PE has led to the development of dapoxetine 
for this specific use.
Dapoxetine
Dapoxetine (Priligy™ Johnson & Johnson, NJ, USA) is a 
novel SSRI, it is similar to the other SSRIs in that it exerts 
its effects through the inhibition of the serotonin reuptake 
transporter.21 In pharmacological studies it has been shown to 
be a highly potent inhibitor of the transporter.25 Dapoxetine 
is a short acting SSRI and so is probably better suited as an 
“on-demand” treatment for PE. There have been several 
randomized placebo controlled trials evaluating dapoxetine. 
Doses of 30 and 60 mg have been used and peak plasma 
concentrations observed 1.01 and 1.27 hours after admin-
istration. Elimination is also rapid, the half life is 1.3 to 
1.4 hours, and there appears to be very little accumulation.26 
This is in contrast to the other SSRI’s that have half lives in 
the order of 1 to 4 days and chronic use results in significant 
accumulation.
In several studies dapoxetine has been shown to signifi-
cantly improve the intra-vaginal ejaculatory latency time as 
compared with baseline and placebo, IELT 1.66 minutes, 
3.03 minutes and 3.15 minutes with placebo, dapox-
etine 30 mg and 60 mg respectively, when the drug was 
taken 30 to 60 minutes before intercourse. When taken 3 
to 4 hours prior to intercourse the IELT was 1.79 minutes, 
3.06 minutes and 3.97 minutes with placebo, 30 mg and 
60 mg dapoxetine respectively.27 Dapoxetine was shown 
to not only increase the IELT significantly, compared with 
placebo, but also to be effective from the first dose when 
taken 1 to 3 hours before intercourse. A further sub-analysis 
of the data this trial showed that men with a perceived greater 
control over their ejaculation also had prolonged IELT, and 
were more likely to be in the dapoxetine arms of the trial.28 
A phase III placebo controlled trial using dapoxetine 60 mg, 
showed significant improvements in patient reported outcome 
measures over a 9-week period.29
A more recent phase III trial from 22 countries, evaluat-
ing dapoxetine 30 mg and 60 mg versus placebo showed that 
IELT was significantly increased with dapoxetine. At the 
end of 24 weeks the IELT had increased from 0.9 minutes 
to 1.9 minutes, 3.1 minutes, 3.5 minutes with placebo, 
dapoxetine 30 mg and 60 mg. All patients reported outcome 
measures were significantly improved with dapoxetine versus 
placebo.30 Currently dapoxetine has not been approved for Drug Design, Development and Therapy 2010:4 
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use in men with PE in the UK, it has been approved in several 
other European countries, however there appears to be evi-
dence that it is efficacious and well tolerated.
PDe-5 inhibitors
Many men with PE, also have concomitant erectile dysfunc-
tion (ED). Whether the man with PE develops secondary ED 
due to anxiety regarding his PE, or whether the man with ED 
ejaculates early during intercourse before his erection fails 
is unknown. There was however a rationale to use PDE-5 
inhibitors in these men, which lead to the hypothesis that 
they may be efficacious in primary PE. A study comparing 
the effectiveness of clomipramine, sertraline, paroxetine, 
sildenafil and pause-squeeze technique in men found that 
there was a 15-fold increase in the IELT for the sildenafil 
group compared with a 3- to 4-fold increase with the other 
treatments, sildenafil was superior in terms of patient sat-
isfaction also.24 A further study comparing sildenafil with 
paroxetine and the squeeze technique in patients with PE but 
no ED, again showed increased IELT in the sildenafil group 
compared to the other two treatment groups.31 Unfortunately 
further studies have failed to show a significant increase in 
IELT with sildenafil, however recent small studies using 
vardenafil compared to placebo32 or sertraline in a random-
ized, prospective, crossover study33 in men with lifelong 
PE, showed a significant increase in IELT with vardenafil 
as well as improvements in other patient reported outcome 
measures. Two small studies have shown that the combination 
of paroxetine and sildenafil has significant improvements in 
IELT compared to paroxetine alone,34,35 unfortunately there 
was a higher incidence of side effects with the combined 
treatment. Clearly further large studies using PDE-5 inhibi-
tors are warranted.
Experimental treatment options
Wise and Watson suggested a novel device based on the 
penile hypersensitivity hypothesis. A de-sensitizing band had 
a pronounced effect on the intra-vaginal ejaculatory latency 
period; the ring was used on a daily basis for 30 minutes, 
for 6 weeks. Once it was worn the man was told that he 
would need to masturbate at least three times per week 
either alone or with a partner for about five minutes, or until 
he was almost at the “point of no return”, this should be 
repeated twice and on the third time he should masturbate 
to ejaculation. This device is no longer available for patient 
use for economic reasons of viability of sales. It may become 
available again as more men present to clinicians for help 
with this condition.36
A surgical procedure consisting of a dorsal neurectomy 
with or without glanular augmentation with hyaluronic acid 
gel has been reported. Although there are reported positive 
results with significantly increased IELT, the two groups that 
underwent dorsal neurectomy or dorsal neurectomy and glan-
dular augmentation, both had significant side effects, includ-
ing penile numbness, paresthesia and pain. The group that 
underwent hyaluronic acid augmentation alone reported no 
adverse side effects.37 Dorsal neurectomy is not in widespread 
practice, however there is now data from five years study on 
the glans augmentation arm of the trial and the hyaluronic 
acid implants were well maintained, showing long-term effi-
cacy for the treatment of premature ejaculation.38
Pulsed radiofrequency neuromodulation has been used 
to treat PE by the desensitization of the dorsal penile nerves. 
This was a small study consisting of 15 patients with primary 
PE. Initial results of this pilot study showed a significant 
increase in the IELT compared to baseline; there were no 
reported problems with pain, penile hypoesthesia, or erectile 
dysfunction post-procedure.39
Conclusion
Premature ejaculation is a widespread condition affecting 
men of all ages. It has significant effects on quality of life 
for both the man and his partner, therefore it is an important 
sexual problem. Currently there are no licensed medications 
used for PE, in the UK. Several pharmacological approaches 
have been used in its treatment, including using topical anes-
thetic agents, the opioid analgesic tramadol, SSRIs, as well 
as PDE-5 inhibitors. Dapoxetine is a short-acting SSRI that 
has been formulated specifically for the treatment of PE, and 
results so far look very promising.
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